Core Viewpoint - BioStem Technologies, Inc. is progressing towards a Nasdaq uplisting by filing its audited consolidated financial statements for the fiscal years ended December 31, 2024, and 2025, marking a significant milestone for the company [1][2]. Financial Progress - The company has published its audited financial statements for 2024 and 2025, which is a crucial step in establishing robust financial reporting processes [2]. - The appointment of a new CFO, auditor, and audit committee chair further emphasizes the company's commitment to improving its financial governance [2]. Corporate Strategy - Listing on Nasdaq is a top priority for BioStem, as it would enhance visibility, improve stock liquidity, provide a more accurate market valuation, and attract top talent [2]. - The company is focused on advancing its corporate initiatives, including the development and commercialization of perinatal tissue allograft products [1][2]. Quality Assurance - BioStem's quality management system and standard operating procedures have been accredited by the American Association of Tissue Banks (AATB), ensuring compliance with current Good Tissue Practices (cGTP) and Good Manufacturing Processes (cGMP) [3]. - The company offers a portfolio of quality brands, including Neox, Clarix, VENDAJE, and American Amnion™ [3]. Company Overview - BioStem Technologies is a publicly traded biomedical innovator specializing in advanced allograft solutions derived from perinatal tissue, utilizing proprietary technologies like BioRetain, CryoTek, and SteriTek [2]. - The company is committed to advancing innovation in regenerative medicine with a growing portfolio of products and expanding clinical research initiatives [2].

Core Insights - BioStem Technologies reported a significant strategic shift following the acquisition of BioTissue's assets, which is expected to diversify its business and enhance its presence in hospital-based care settings [3][4][10] Financial Performance - In Q4 2025, BioStem's revenue was $10.1 million with a gross margin of 97%, but operating expenses increased to $17.3 million due to an $8.8 million allowance for potentially uncollectible receivables [5][13][15] - The company anticipates Q1 2026 revenue to be between $5 million and $6 million, reflecting a decline in physician office revenue due to changes in Medicare reimbursement [6][17] Strategic Initiatives - The acquisition of BioTissue introduced new products, including Neox and Clarix, and allowed BioStem to pivot towards hospital-based care, reallocating commercial resources accordingly [7][10] - Management is focusing on expanding its sales force and launching medical education programs to support its new product offerings and enhance market penetration [20] Market Opportunities - BioStem identified several specialty markets as growth opportunities, including orthopedics, urology, and chronic wound care, representing a combined market potential of approximately $23 billion [12] Clinical Developments - The company plans to publish additional analyses from its diabetic foot ulcer (DFU) clinical trial and expects to release top-line results for its venous leg ulcer (VLU) study in the coming months [1][9] Operational Adjustments - Management noted that changes in CMS reimbursement are prompting clinicians to adjust their protocols, leading to a significant decline in physician office revenue in early 2026 [8][18] - BioStem is actively seeking financing opportunities to support its operations and commercial growth amid expected cash consumption throughout 2026 [18] Audit and Compliance - The company is in the process of completing independent audits for fiscal years 2024 and 2025, which are expected to be finalized soon as part of its plans for a Nasdaq uplisting [21]

Core Insights - BioStem Technologies, Inc. reported a significant decline in revenue for Q4 2025, with net revenue of $10.1 million, a 55% decrease compared to Q4 2024, primarily due to reimbursement uncertainty and competitive pressures [5][6] - The company completed the acquisition of BioTissue Holdings Inc. in January 2026, which is expected to enhance its product portfolio and commercial reach [9][10] - BioStem anticipates first quarter 2026 revenue to be between $5 million and $6 million, with expectations for growth in the hospital business in the second half of the year [12] Recent Financial and Business Highlights - CEO Jason Matuszewski emphasized the company's strengthened position and diversification following the BioTissue acquisition, which expands its market presence [3] - The gross profit margin for Q4 2025 was 97%, up from 84% in Q4 2024, attributed to a shift in product mix [5] - Operating expenses increased to $17.3 million in Q4 2025 from $10.7 million in Q4 2024, largely due to charges for potentially uncollectible accounts receivable [6] Financial Results Overview - For the full year 2025, net revenue was $47.5 million, down from $69.7 million in 2024, driven by lower wound care volume [8] - Gross profit for 2025 was $44.4 million, or 94% of net revenue, compared to $55.9 million or 80% in 2024 [10] - The company reported a GAAP net loss of $6.6 million for 2025, a significant decline from a net income of $31 million in 2024 [11] Cash Position and Future Outlook - As of December 31, 2025, cash equivalents totaled $29.5 million, which decreased to approximately $16 million post-BioTissue acquisition [7] - The company expects to drive sequential and year-over-year growth in the hospital business after integrating the BioTissue assets and expanding its salesforce [12]

Company Presentation MARCH 2026 Forward Looking Statements Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions. The Company's actual results and financial condition may differ materially from those indicated in the forward-looking statements. The following is a list of risks, among others, that could cause actual results to differ materially from those contemplated by the forward-looki ...

Summary of BioStem Technologies Conference Call Company Overview - **Company**: BioStem Technologies - **Industry**: Regenerative Medicine, Wound Care - **CEO**: Jason Matuszewski - **Conference**: 46th Annual TD Cowen Healthcare Conference Core Points and Arguments - **Mission**: BioStem aims to create and deliver advanced wound healing technologies, addressing the significant challenges posed by chronic and acute wounds, which have an estimated economic impact of over $30 billion annually in the U.S. [2][4] - **Key Pillars**: The company is built on three pillars: differentiated technology, strong operational and clinical foundation, and a scalable growth engine [3] - **Technologies**: BioStem's technology platform includes BioREtain, CryoTek, and SteriTek, with a focus on perinatal-derived allograft brands like Neox and Clarix [3] - **Intellectual Property**: The company holds 58 issued U.S. patents and 68 pending patents, showcasing a strong IP portfolio [3] - **Market Opportunity**: BioStem targets a multi-billion dollar market, with a soft tissue allograft opportunity exceeding $23 billion across six core segments: orthopedics, chronic wound care, foot and ankle, urology, spine, and women's health [5] Financial Performance - **Revenue**: In 2025, the surgical revenue generated approximately $29 million, largely unaffected by CMS's wound pricing changes [6] - **EBITDA**: The BioTissue surgical and wound care assets delivered a single-digit positive EBITDA in 2025 [17] - **Cash Position**: The company has around $16 million in cash on the balance sheet, indicating a strong position for future investments [18] Market Dynamics - **Reimbursement Changes**: The transition from a bundled payment system to a fixed rate per square centimeter allows for treatment of larger wounds, which is expected to enhance market access [12][13] - **Challenges**: There are concerns regarding access to products in physician offices and mobile wound care settings due to the new reimbursement rates [27][28] - **Regulatory Environment**: The company is focused on generating clinical evidence to support reimbursement and market access, particularly in light of changing LCDs and payment methodologies [29] Strategic Initiatives - **Acquisition Impact**: The acquisition of BioTissue has expanded BioStem's product offerings and market reach, with a focus on diversifying the portfolio and driving growth [5][10] - **Sales Expansion**: The company has increased its sales force with 18 direct representatives and over 30 independent agents, aiming to penetrate new markets and enhance distribution [20] - **Future Products**: BioStem is looking forward to a 510(k) product launch in the middle to back half of the year, which will further diversify its offerings [4][19] Leadership and Management - **Management Team**: The company has assembled a leadership team with extensive experience in clinical research, commercial education, manufacturing, regulatory, and finance [16] - **New Appointments**: Barry Hassett has been appointed as Chief Commercial Officer, and Lita Lilly as VP of Sales, both bringing valuable experience from BioTissue [17] Conclusion - **Long-term Vision**: BioStem is positioned to capitalize on opportunities in regenerative medicine, leveraging its platform of perinatal tissues and focusing on evidence-based approaches to support its growth strategy [21]

Core Insights - BioTissue Holdings, Inc. has completed the sale of its non-ocular Surgical and Wound Care business to BioStem Technologies, Inc., allowing BioTissue to focus on ocular market leadership and innovation in eye care solutions [1][2][3] Company Overview - BioTissue specializes in utilizing human birth tissue for regenerative healing, particularly in treating acute and chronic ocular surface conditions [4] - The company has developed a portfolio of cryopreserved amniotic membrane products using proprietary CryoTek® technology, which preserves the tissue's structural and functional integrity [4] - BioTissue has conducted over 1 million human procedures with its products and has over 420 peer-reviewed publications supporting its technology [4] Strategic Focus - Following the divestiture, BioTissue will concentrate on advancing interventional therapies for ocular conditions, including products like Prokera, CAM360 AmnioGraft, and AmnioGuard [2][3] - The company aims to prioritize product innovation, professional education, and comprehensive customer support within the eye care market [2] Partnership with BioStem - BioStem Technologies will acquire exclusive rights to BioTissue's Neox and Clarix product lines, integrating BioTissue's surgical sales team into its commercial organization [2][3] - BioStem's CEO highlighted the complementary strengths of BioTissue's portfolio to their existing business, indicating a strong potential for growth and improved patient outcomes [3]

Core Viewpoint - BioStem Technologies, Inc. has acquired the surgical and wound care business of BioTissue Holdings Inc. for approximately $15 million, enhancing its commercial organization and expanding its market reach in advanced wound care [1][4][5]. Group 1: Acquisition Details - BioStem has closed a definitive asset purchase agreement with BioTissue, acquiring its full portfolio of surgical and wound care assets, including the Neox and Clarix product lines [2][3]. - The acquisition includes a nationwide network of sales representatives and independent agents, along with key GPO contracts, significantly expanding BioStem's commercial capabilities [2][3]. - The total upfront cash payment for the acquisition is approximately $15 million, with potential additional payments of up to $25 million based on regulatory and commercial milestones [4][5]. Group 2: Financial Impact - The acquired assets generated approximately $29 million in sales in 2025 and are expected to contribute positively to BioStem's EBITDA in 2026 [5]. - Post-acquisition, BioStem's cash and restricted cash balance is approximately $16 million [5]. Group 3: Leadership Changes - Barry Hassett has been promoted to Chief Commercial Officer to lead the newly combined commercial team, bringing over 25 years of industry experience [6].